Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HarMono-T (perflutren)
- Development stage
- Unknown
- Lead developer
- Solstice Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HarMono-T is a monodisperse ultrasound contrast agent (UCA) developed by Solstice Pharmaceuticals. It utilizes perflutren (octafluoropropane) gas encapsulated within a lipid shell to form microbubbles of uniform size. Unlike traditional polydisperse contrast agents that contain microbubbles of varying diameters, HarMono-T is engineered to be monodisperse, which is intended to optimize the acoustic resonance of the bubbles at specific ultrasound frequencies. This uniformity enhances the sensitivity and resolution of contrast-enhanced ultrasound (CEUS) imaging, particularly for harmonic imaging. The agent is primarily being investigated for the characterization of indeterminate kidney lesions, where it improves the visualization of renal microvascular blood flow and perfusion patterns to assist in differentiating between benign and malignant masses. HarMono-T is currently undergoing Phase I/II clinical evaluation.
- Brand names
- HarMono-T
- Other names
- octafluoropropaneperflutren lipid microspheres
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on HarMono-T (perflutren).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HarMono-T (perflutren).